Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
2009
This observer-
blind studycompared the prophylactic human papillomavirus (
HPV)
vaccines,
Cervarix™ (GlaxoSmithKline) and
Gardasil® (Merck), by assessing immunogenicity and safety through one month after completion of the three-dose vaccination course. Women (n=1106) were stratified by age (18–26, 27–35, 36–45 years) and randomized (1:1) to receive
Cervarix™ (Months 0, 1, 6) or
Gardasil® (Months 0, 2, 6). At Month 7 after first vaccination, all women in the according-to-protocol cohort who were seronegative/DNA negative before vaccination for the HPV type analyzed had seroconverted for HPV-16 and HPV-18 serum
neutralizing antibodies, as measured by
pseudovirion-based neutralization assay (PBNA), except for two women aged 27–35 years in the
Gardasil® group who did not seroconvert for HPV-18 (98%). Geometric mean titers of serum
neutralizing antibodiesranged from 2.3–4.8-fold higher for HPV-16 and 6.8–9.1-fold higher for HPV-18 after vaccination with
Cervarix™ compared with
Gardasil®, across all age strata....
Keywords:
-
Correction
-
Source
-
Cite
-
Save
-
Machine Reading By IdeaReader
65
References
346
Citations
NaN
KQI